NEW HAVEN, Conn., April 28, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, ...
SAN JOSE, Calif., Aug. 1, 2024 /PRNewswire/ -- BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally "hard-to-drug" targets, today announced an expansion to ...
(MENAFN- GetNews) Creative Biolabs has established a specialized team of scientists working on proteolysis targeting chimeric molecule (PROTAC) related projects, providing one-stop solutions of PROTAC ...
Arvinas, Inc. announced promising preclinical results for ARV-393, a targeted protein degrader aimed at treating non-Hodgkin lymphoma, particularly high grade B-cell lymphomas. Data showed that ...
Proteins that are commonly mutated and overexpressed in cancers are called oncoproteins and are typical targets for cancer therapies. Cancer treatment faces significant challenges due to the presence ...
Researchers from Nankai University and collaborating institutions have identified a novel proteolysis targeting chimera (PROTAC) molecule that effectively and selectively degrades multiple ...
– ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback